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Abstract
Background: Hepatitis C virus roots a chronic liver disease. Currently approved treatment strategy includes
administration of alpha interferon and ribavirin combined therapy for 24-48 weeks. One of the predictor of
sustained virological response is an early virological response to treatment characterized as rapid response. Hyper
variable region 1 (HVR1) of E2 protein is responsible for viral entry and acts as a target for neutralizing antibodies.
Any mutation in this region would effect virus interaction with target cell and viral persistence.
Methods: Thirty one clones of six pre-treatment samples subjected to combination therapy were investigated.
Three of the patients were rapid responders (R1, R2 and R3) and two were breakthrough responders (BT1 and BT2).
Envelope 2 gene was amplified, cloned and sequenced. Amino acid substitution, frequency, composition and
antigenic properties of HVR 1 of E2 protein were studied.
Results: In both rapid responders (R.R) (14 amino acid sites) and breakthrough responders (BT.R) (13 amino acid
sites) half of the amino acid sites were either conserved or resistant to any physiochemical change due to amino
acid substitution. It also indicated that average composition of hydrophilic and basic amino acids were
comparatively lower in rapid responders than other samples affecting probable interaction of virus with target cells.
A central non antigenic region was constant among the breakthrough responders but differed in length
significantly among rapid responders reflecting the adaptive nature of HVR1 to the immune response.
Conclusions: We observed that although HVR1is quite variable region in HCV 3a patients responding differently to
treatment it still maintains its physiochemical properties for its proper functioning and viability.
Background
HCV roots a persistent infection which advances
towards chronic hepatitis, liver steatosis, cirrhosis and
hepatocellular carcinoma [1-3]. It is a blood borne infec-
tion that infects 270-300 million people worldwide [4].
In Pakistan it affects above 10 million people, almost
8-10% of the total population [5,6].
The standard therapy for HCV treatment adds up to
taking Alpha-interferon 3 MU three times a week [7]
and 1000-1200 mg of nucleoside analogue ribavirin per
day/24-48 weeks [8]. HCV genotype and the viral load
figure out the antiviral response and the rate is higher
for genotype 2 and 3 than for genotype 1 [9]. Genotype
3a, the most respondent to therapy, which is frequent
genotype in Pakistan [10].
In HCV E1 and E2 protein are heterogeneous, espe-
cially hyper variable regions which include HVR1, a 27
amino acid sequence (81 nucleotides) [11,12]. Many stu-
dies stated that HVR1 lower complexity favours response
[13]. Some studies however pointed out negative correla-
tion between genetic heterogeneity and treatment
response [14,15]. It has been suggested that HVR1 region
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any medium, provided the original work is properly cited.of E2 protein act as a target for neutralizing antibodies
[16] and is involved in viral entry [17,18]. Rapid changes
in the amino acids of the HVR1 allow HCV to escape
humoral immunoglobulins and cause the infection to
persist. Therefore analysis of genetic complexity of this
region is imperative for understanding the role of envel-
ope gene specifically HVR1 in virus interaction to target
cells and its persistence which will effect the outcome of
treatment. Rapid responders have recently been identified
as positive predictors of sustained virological response in
Pakistan [19]. Therefore our study was focused on the
g e n e t i cc o m p l e x i t yo fH V R 1o fe n v e l o p e2p r o t e i ni n
rapid responders in the pre-treatment samples with an
aim of identifying some significant mutations or pattern
of mutations associated specifically with the rapid
responders. This study can therefore be helpful in pre-
dicting the outcome of treatment response even before
the onset of treatment and tailoring the treatment regi-
men according to the predicted treatment response.
Results
Amino acids substitution analysis in HVR1
In HVR1, four amino acids position 2, 6, 19 and 23 were
conserved in all the 31 variants. Conserved and variable
sites among variants of rapid responders and among
variants of breakthrough responders were also analyzed
(Table-1 &2). Total number of conserved and variable
sites was almost same in both groups but amino acid
positions differed. Amino acid position 3, 7, 9 and 15
were conserved in breakthrough responders but had
amino acid substitution in rapid responders. Conversely
amino acids 13, 18, 24 and 26 were conserved in rapid
responders but variable in breakthrough responders.
Multiple amino acid substitution at single site was more
common in rapid responders than in breakthrough
responders for example at position 1 and 4 amino acids
histidine (H) and threonine (T) were replaced by four
other amino acids in rapid responders whereas in break-
through responders at these positions single substitu-
tions were observed.
Variable sites in rapid responders have some sites that
maintained their physiochemical properties, these
include amino acid 9 and 20 which were exclusively
hydrophobic and non-polar amino. Another physio-
chemical stable site was of amino acid 21, which was
exclusively polar neutral amino acid site, however one
of the variant harbored polar acidic amino acid, aspartic
acid (D) at amino acid position 21.
In breakthrough responders variable sites that main-
tained their physiochemical properties were amino acid
5 and 8 that were exclusively polar neutral sites. Amino
acid 16 was exclusively non polar and hydrophobic, this
amino acid is a conserved site in rapid responders as
well. Amino acid 27 was also exclusively polar and
hydrophilic in breakthrough responders, whereas in
rapid responders this site was almost conserved with
polar hydrophilic properties and very rare non polar
amino acid substitution (1 out of 15 in our case).
Amino acid 16 and 27 maintained their physiochemical
properties despite of amino acid substitution in break-
through responders. Amino acid 16 was at conserved site
while amino acid 27 maintained its physiochemical prop-
erties in rapid responders thus amino acid 16 and 27 can
be considered as sites which are resistant to a functional
change.
Similarly amino acids 9, 20 and 21 maintained their
physiochemical properties in rapid responders were
either at conserved sites in breakthrough responders or
were resistant to physiochemical changes.
Five amino acids sites that were conserved sites in
both rapid responders and breakthrough responders are
2, 6, 10, 19 and 23. Five sites that were either conserved
sites in one of the two groups or that maintained their
physiochemical properties in both the groups were 16,
27, 9, 20 and 21. In total ten amino acids sites were
exclusively conserved between samples responding dif-
ferently to the treatment. Remaining seventeen sites
were displaying different physiochemical properties.
In rapid responders ten amino acid sites were con-
served. Four amino acid sites were not conserved but
maintained their physiochemical properties. Therefore
among rapid responders more than half part of the
HVR1 (fourteen amino acid sites) were stable function-
ally. In breakthrough responders nine amino acids were
conserved. Amino acid substitution in four amino acid
sites resisted any physiochemical change. Therefore like
Table 1 amino acids substitution in HVR1 of E2 protein (Rapid responder group)
H T YTTG GT A A RNT KGL A GL FY P GA K Q K
1 2 3456 78 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
N5 Y8 T5 T10 G10 S7 V5 S5 S7 S10 G10 T7 F14 S10 R5 S10 N10
V4 H7 V5 V4 S5 K5 I5 R5 T5 R5 S5 V5 L1 T4 S5 K5 K3
Q2 I3 A1 N3 A5 H3 N2 A3 D1 P5 R1
H2 P1 Y2 W1
K1 L1
Amino acid substitution at each amino acid position analyzed from pre-treatment patient samples that belong to rapid responder group (R.R). R.R group( 3
samples and 15 clones) contains 10 conserved sites and 17 variable sites.
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remained stable functionally.
Amino acid frequency
Frequency of individual amino acid in HVR1 was com-
pared between samples (Figure 1). Some of the amino
acids were equally frequent among all the samples. For
example amino acid proline and tyrosine were equally
frequent in all the samples but frequency of most of the
amino acids was quite divergent between samples.
Change in amino acids frequency was also analyzed
within the sample (data not shown) i.e. at intrahost level
since we had observed intrahost nucleotide variations.
There were more amino acid substitutions among the
variants of rapid responders and so there was divergent
amino acid frequency among rapid responders but only
in case of R1 sample. Amino acids alanine, glutamine,
serine and threonine frequencies varied between variants
of R1. However in case of other samples change in
amino acid frequency was almost unnoticeable.
Amino acid composition
Comparison between breakthrough and rapid responder
group indicated that polar amino acids were slightly
higher in rapid responder compare to breakthrough
responder. In R.R group 56.73% of amino acids were
polar and 43.28% of amino acids were non polar. In BT.
R group 49.88% of amino acid were polar and 50.12% of
amino acids were non polar. Among polar, neutral polar
amino acids were more frequent than charged amino
acids. Average composition of hydrophobic amino acids
was greater than hydrophilic amino acids. Composition
of hydrophilic amino acid was slightly greater in BT.R
group (18.52%) than R.R group (17.6%). Acidic amino
acids composition was slightly greater in breakthrough
responders (2.22%) than in rapid responders (0.23%).
(Tables-3 &4)
Analysis of antigenic profile
All the variants supported the presence of two antigenic
region separated by non antigenic region. Antigenic
region towards the carboxyl terminal extended from
amino acid 20-27 in all the samples and remained con-
stant among variants. However the length of antigenic
region towards the amino terminal varied from sample to
sample. It extended from position 4-11 in breakthrough
responders and remained constant in all the variants.
However in rapid responders this antigenic region was
quite variable. R1 was least antigenic with a slightly raised
peak at position 6 and 10 (remember these amino acid
positions were conserved). In R2 antigenic region
extended from position 6 to 11 and remained constant in
all variants of R2. In sample R3 antigenic region started a
bit earlier and ended a bit earlier from position 4 to 8
(Figure 2).
Discussion
Sequences of HVR1 of 31 variants from six samples
consisting of 3 rapid responders (R1, R2 and R3) and
two breakthrough responders (BT1 and BT2) were com-
pared at amino acid level. Total number of conserved
and variable sites remained almost same in both the
groups opposing the common assumption that respon-
ders harbors less variability than the non responders.
Fourteen out of twenty seven amino acid positions were
resistant to any change in physiochemical properties in
rapid responders. On the other hand half of the amino
acids were conserved or resistant to physiochemical
shifts in breakthrough responders. Although number of
conserved and variable sites was same in both groups
Table 2 amino acids substitution in HVR1 of E2 protein (Breakthrough responders)
H TY TT GG T AA RNTKG LAGL FY P G AK Q K
1 23 4567 8 91 011 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
S9 T9 S9 S9 R9 D9 V8 H5 L9 V9 G9 F12 S14 P9 A9 Q9 Q12 R9
G5 V5 T5 Q5 S5 H5 T5 K9 F5 T5 N5 S A5 P5 K5 R2 N5
I1 L
Amino acid substitution at each amino acid position analyzed from pre-treatment patient samples that belong to breakthrough responders (B.T). B.T group (2
samples and 14 clones) contains 9 conserved sites and 18 variable sites. Conserved sites are shown in bold and non-italic letters.
Figure 1 Frequency of amino acids in the HVR 1 of samples
responding differently to treatment. Graphical representation of
frequency of twenty amino acids in the HVR 1 of samples
responding differently to treatment (rapid responders R.R,
breakthrough responders B.T and sample showing response at the
end of treatment E.T.R). Most frequently present amino acids were
serine (S), Threonine (T), Glycine (G) and Alanine (A).
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breakthrough responders. Ten amino acids sites were
exclusively conserved between samples responding differ-
ently to the treatment. Half of these sites were either con-
served in one of the two groups or retained their
physiochemical properties. Other half of the amino acids
did not harbor any substitution at all. Another study con-
firmed that despite of high variability in HVR1, at most of
the position hydropathic characters remained conserved
[17]. Another study proves the conservation of HVR 1
composition, length and amino acid substitution [20].
It has been already noted that neutral amino acids are
more frequent in HVR1 than in common proteins [17]. It
has been observed previously that neutral amino acids
are more frequently present in HVR1 followed by hydro-
phobic and hydrophilic amino acids, our study supports
the observation as neutral amino acids were found to be
more frequent in HVR1 of both RR and BTR
Hydrophilic residues are exposed on the surface and
are involved in interactions with other molecules
whereas hydrophobic amino acids anchor E2 to core
and maintains conformation of HVR1 [17]. In the pre-
sent study composition of hydrophilic amino acids was
slightly higher in breakthrough responders (18.52%)
than in rapid responders (17.6%) whereas composition
of hydrophobic amino acids was almost same in both
the groups (31.71% in rapid responders and 31.85% in
breakthrough responders). Among hydrophillic amino
acids, those bearing basic properties were more com-
mon than those bearing acidic properties, confirming
HVR1 to be a basic stretch as described previously by
Penin, Combet et al. The basic nature of HVR1 made it
to interact with lipids, GAG, s or proteins bearing nega-
tive charges [17,21]. Composition of basic residues was
again slightly higher in breakthrough responders (12.1%)
than rapid responders (10.8%). From above discussion
we can conclude that changes in composition of hydro-
philic and basic residues can lead to changes in the
interaction with low density lipoprotein (LDL) and
GAG’s that are proposed to be involved in virus interna-
lization [22] and receptor virus interaction [23] respec-
tively thereby affecting infection cycle of HCV.
Most frequent amino acids in HVR1 were glycine (G).
threonine (T), serine (S) and alanine (A) (Figure 1).
These amino acids are small in size and flexible amino
acids that can attain any conformation and their fre-
quent presence balance the less flexible large amino
acids [17]. However their frequency differed between
samples as rapid responders had greater frequency of
these amino acids (56.25%) than breakthrough respon-
ders (52.1%) making the earlier one more flexible. This
ensures slight conformational variability between the
two groups but these amino acids are either neutral or
hydrophobic which means they would not be involved
Table 3 Amino acid composition (polar and non polar amino acids) in HVR1 of E2 protein
HVR 1 Polar a.a composition Non polar a.a composition
+ve charged (basic) - ve charged(acidic) Neutral
RR group (15 variants) Lys(K)3.94 Asp(D).23 Ser(S)18.29 Ala(A)9.95
His(H)3.01 Glu(E)- Thr(T)15.28 Val(V)5.56
Arg(R)3.94 Gln(Q)4.17 Leu(L)7.87
Cys(C)- Ile(I)1.85
Asn(N)5.09 Gly(G)12.73
Tyr(Y)2.78 Trp(W)0.23
Phe(F)3.47
Pro(P)1.62
Met(M)-
Average 10.89 .23 45.61 43.28
BT group (14 variants) Lys(K)3.21 Asp(D)2.22 Ser(S)11.60 Ala(A)11.36
His(H)3.70 Glu(E)- Thr(T)10.62 Val(V)5.43
Arg(R)5.19 Gln(Q)6.67 Leu(L)6.42
Cys(C)- Ile(I).25
Asn(N)2.72 Gly(G)18.52
Tyr(Y) 3.95 Trp(W)-
Phe(F)4.44
Pro(P)3.70
Met(M)-
Average 12.1 2.22 35.56 50.12
Comparison of average composition of twenty amino acids between rapid responders and breakthrough responders. Average composition of polar and non
polar amino acids in HVR1 of rapid responders (R.R) and breakthrough responders (B.T).
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also compared which revealed the presence of two anti-
genic domains as previously reported [17,24]. The anti-
genic domain towards the carboxyl terminal was stable
however the one towards amino terminus was variable
between samples. In other study antigenic characteristics
at the amino terminus differed between lineages [25].
Our study confirmed the presence of a non antigenic
domain in genotype 3a samples as reported in genotype
1b [24]. Results indicated that due to amino acid substi-
tution at multiple sites antigenicity of HVR1 changed.
Changes were quite significant among rapid responders
than in breakthrough responders where antigenic region
was quite constant in all variants that could be signifi-
cant for the compatibility of HCV to the host immune
response.
From our study and many other studies that stresses
on the assumption that despite of uncontrolled hyper
variability HVR1 maintains high conservation at many
amino acid positions, and substitutions at variable sites
do not maintain a specific pattern [26,27] We can con-
clude that although hyper variable region is quite vari-
able region it still maintains its physiochemical
properties which help it maintaining its structure
ensures its viability and proper functioning. When com-
paring rapid responders with breakthrough responders
we found slight differences as breakthrough responders
were comparatively more likely to interact with target
cells and cause infection.
Since this study points out only slight differences
between rapid responders and breakthrough responders,
further studies are still needed to be done on large
number of samples to confirm the results and at the
same time properties of other hyper variable regions in
rapid responders are still needed to be studied.
Conclusions
Hypervariable region is quite variable region in HCV 3a
pretreatment samples responding differently to the
treatment but it still maintains its physiochemical prop-
erties for proper functioning. Slight differences in rapid
responders and breakthrough responders indicated that
rapid responders were less likely to interact with target
cells and cause infection. Antigenic variability was more
significant in rapid responders than in breakthrough
responders.
Methods
Patients and samples
Six patients infected with HCV 3a genotype were
selected for this study. All of them were subjected to a
combination therapy consisting of recombinant inter-
feron (3 MU three times a week, subcutaneously) and
ribavirin (10 mg/kg per day) for 6 months. Serum sam-
ples taken before the onset of treatment were examined.
Three patients (R1, R2, and R3) showed a rapid
response to treatment as defined by negative HCV RNA
(<500 IU/ml) after 1 month of treatment. Two patients
( B T 1a n dB T 2 )s h o w e dab r e a k t h r o u g hv i r o l o g i c a l
response during treatment followed by reappearance of
HCV RNA at the end of treatment. One of the patient
showed negative HCV RNA at the end of treatment and
was defined as end of treatment response (ETR). The
subjects gave informed consent to participate and the
study was conducted in accordance with the 1964
Declaration of Helsinki and Guidelines for Good Clinical
Research Practice in Pakistan. The study was approved
by Ethics Committee of Molecular Virology Division.
HCV RNA extraction and amplification of E2
Hepatitis C viral RNA was extracted from 100 μlo f
stored serum of the patients using Gentra RNA isolation
Kit (Gentra, Purescript Technologies, USA) according to
the kit protocol. cDNA synthesis of extracted RNA (10
μl) was done at 37°C for 50 min and 42°C for 10 min
using 200 units of Moloney Murine Leukemia Virus
reverse transcriptase (M-MLV RTase) (Invitrogen) and 8
Units of RNase inhibitor in a 20 μl of reaction with E2
Table 4 Amino acid composition (hydrophilic,
hydrophobic and neutral amino acids) in HVR1 of E2
protein
Hydropathic composition
HVR 1 Hydrophobic Neutral Hydrophillic
RR group (15 variants) Leu (L) 7.87 Thr (T) 15.28 Arg (R) 3.94
Ile (I) 1.85 Glu (E)- Lys (K)3.94
Phe (F) 3.47 Gly (G) 12.73 Asn (N) 5.09
Trp (W) .23 Ser (S) 18.29 His (H) 3.01
Val (V) 5.56 Gln (Q) 4.17 Pro (P) 1.62
Met (M) - Asp (D) .23
Cys (C) -
Tyr (Y) 2.78
Ala (A) 9.95
Average 31.71 50.7 17.6
BT group (14 variants) Leu (L) 6.42 Thr (T) 10.62 Arg (R) 5.19
Ile (I) .25 Glu (E) - Lys (K)3.21
Phe (F) 4.44 Gly (G) 18.52 Asn (N) 2.72
Trp (W) - Ser (S) 11.60 His (H) 3.70
Val (V) 5.43 Gln (Q) 6.67 Pro (P) 3.70
Met (M) - Asp (D) 2.22
Cys (C) -
Tyr (Y) 3.95
Ala (A) 11.36
Average 31.85 49.63 18.52
Comparison of average composition of twenty amino acids between rapid
responders and breakthrough responders. Average composition of
hydrophilic, hydrophobic and neutral amino acids in HVR1 rapid responders
(R.R) and breakthrough responders (B.T).
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CAAAGC). For nested PCR amplification of entire E2
gene two sets of primers were optimized. The first
r o u n do fP C Rw a sd o n ew i t h1 0p Mo fE 2o u t e ra n t i -
sense primer and with 10 pM of outer sense primer
(TCCTGGTAGTGCTGCTGCTA). Four microliter of
the first round PCR products was used as a template for
second round of nested PCR using inner sense (GAAA-
CCCACGTCACCGGGGGAA) and inner antisense
primers (CGCCTCCGCTTGGGATATGAGTAACA).
Figure 2 Antigenic profile of HVR1. Graphs comparing antigenicity computed by method of parker. (2) of HVR1 between breakthrough
responders (BT1 BT2), rapid responders (R1 variants, R2 and R3) along HVR1 at each amino acid position.
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rounds: initial denaturation at 94°C for 2 min followed by
35 cycles consisting of denaturation at 94°C for 45 sec, pri-
mer annealing at 50°C for 45 sec and primer extension at
72°C for 3 min followed by a final extension of 10 min.
The amplified products were visualized on 1.2% agarose
gel stained with ethidium bromide under UV transillumi-
nator after electrophresis. The required bands were excised
and DNA was purified from the agarose gel with Silica
Bead DNA Gel Extraction Kit (Fermentas Inc. Germany).
Purified DNA was suspended in depc treated water and
used for cloning and sequencing.
Cloning of E2
Purified E2 amplified products were directly ligated to
50 ng of PCR 2.1 vector (TA Cloning Kit; Invitrogen).
The product was transformed into chemically compe-
tent TOP10F’ cells by incubating the entire ligation
reaction along with competent cells on ice for 30 min
then a 1 minute heat shock was given to cells at 42°C
after which the cells were immediately transferred to
ice. Then the cells were incubated with 500 ul of Luria-
Bertani (LB) medium at 37°C for 1 hour. Successfully
transformed cells were selected on LB agar plate supple-
mented with 100 μg/ml ampicillin and 12.4 ug/ml tetra-
cycline. Plates were subjected to overnight incubation at
37°C. Clones carrying E2 gene were confirmed by colony
PCR. 50 ul of culture was centrifuged at 13000 rpm for
2 min. supernatant was discarded and pellet was resus-
pended in 50 μl of 1X T.E. resuspended pellet was sub-
jected to heat shock at 100°C for 10 min followed by
centrifugation at 13000 rpm for 2 min. Supernatant that
was supposed to contain the plasmid was used as a tem-
plate for the PCR reactions. These PCR reactions were
prepared both with 10 pmol vector-specific primers
M13 forward (TAATACGACTCACTATAGGG) and
M13 reverse (TAGAAGGCACAGTCGAGG) and with
gene specific primers (E2 inner sense and inner anti-
sense). Bands of size approximately 1056 bp with gene
specific primers and 1183 with vector specific primers
were visualized under UV confirmed successful cloning.
Plasmid was isolated from cultures containing E2 clones
using a Plasmid Miniprep Kit, (Fermentas Life Science
technologies USA) according to manufacturer’s protocol.
From each patient 5-10 positive clones were randomly
selected for sequencing.
Sequencing
For each clone, both strands of E2 gene were sequenced
with M13 forward and reverse primers by Applied bio-
systems prism dye termination method according to the
manufacturer’s instructions (Big Dye Deoxy Termina-
tors; Applied Biosystems, Weiterstadt, Germany).
Sequencing was performed on automated sequencer
(Applied Biosystems; 3100 DNA Analyzer). Sequencing
PCR reaction was performed with profile; 96°C for 15 sec,
50°C for 10 sec, 60°C for 4 min repeated 35 times. Labeled
DNA was then purified with 2 μl of 3M Sodium Acetate
and 2 μl of 125 mM EDTA followed by precipitation with
26 μl 100% ethanol. After 15 min incubation at room tem-
perature DNA was centrifuged for 30 minutes at 2800
rpm at 4°C. Washing was done with 36 μl of 70% ethanol.
Pellet was air dried and rehydrated in 12 μl formamide.
Pellet was chilled on ice after it was heat shocked at 95°C
for 5 minutes. Air dried pellet was then analyzed using an
ABI prism sequencer. A set of 31 variants was analyzed
containing 2-10 clones selected from each patient.
(5 clones from patient R1, R2, R3, BT2; 9 clones from
patient BT1 and 2 clones from patient ETR). Sequences
were analyzed with the Chromas LITE programme (ver-
sion 2.01; Technelysium Pty Ltd).
Amino acid heterogeneity analysis of HVR1
Amino acid heterogeneity analysis was done by aligning
amino acids using Bioedit clustal W programme. These
aligned sequences were then analyzed using MEGA ver-
sion 4.1 [28]. Number of conserved sites, number of
variable sites, amino acid substitution at each amino
acid position (1-27 a.a) and amino acid composition was
calculated for each variant and then comparisons were
made between samples, between variants and groups.
Amino acid frequency, count of hydrophilic and hydro-
phobic residues and count of charged and uncharged
residues were done by CLC workbench software http://
www.clcbio.com.
Antigenic profile
Antigenic regions were identified within the HVR1 of
Envelope protein by analyzing antigenic profiles of all
the variants by the method of Parker et al. [29].
Nucleotide sequence accession numbers
Accession numbers of nucleotide sequences submitted
to GenBank are HM590012 to HM590017, HM584119
to HM584121, HM462252, HQ184929 to HQ184935,
HQ202715 to HQ202721 and HQ189124 to HQ189130
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